摘要
目的:系统回顾复发或难治性套细胞淋巴瘤药物经济学评价,为今后该疾病治疗方案的决策以及开展药物经济学评价提供参考。方法:系统检索PubMed、EMbase、The Cochrane Library、中国知网、万方数据库和维普网,搜集整理国内外复发或难治性套细胞淋巴瘤的药物经济学评价相关研究,检索时限均为建库至2024年2月6日,采用2022版CHEERS量表对纳入文献进行质量评价,并对提取资料进行系统评价。结果:共纳入6篇文献,文献总符合率均在80%以上,分区生存模型是最常用的分析模型;干预组疗效数据来源于临床试验,对照组疗效数据来源于临床试验、真实世界研究或文献综述,疗效数据为患者水平数据或KM曲线模拟;效用多来源于已发表文献,成本均为直接成本,主要来源于已发表文献和医保数据库等;结局指标主要为质量调整生命年(quality-adjusted life years,QALYs)和生命年(life years,LYs);敏感性分析采用确定性敏感性分析和概率敏感性分析,主要影响因素为药品成本等。结论:现有的国内外复发或难治性套细胞淋巴瘤的经济性评价研究数量较少,药物经济学评价报告未严格遵守CHEERS量表的要求,存在内容不完整的问题,在模型设置的研究时限、效用数据获取、成本组成等方面,仍存在一些不足之处亟待解决。
OBJECTIVE To systematically review the pharmacoeconomic evaluations of relapsed or refractory(R/R)mantle cell lymphoma(MCL),providing a reference for future decision-making on treatment plans and pharmacoeconomic evaluations of the disease.METHODS A systematic search was conducted in PubMed,EMbase,The Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang Database,and VIP Network to collect and organize relevant studies on the pharmacoeconomic evaluation of R/R MCL from the establishment of the database to February 6,2024.The quality of the included literature was assessed using the 2022 version of the Consolidated Health Economic Evaluation Reporting Standards(CHEERS)scale,and a systematic review of extracted data was performed.RESULTS A total of 6 studies were included,with an overall compliance rate of over 80%.The partitioned survival model(PSM)was the most commonly used analytical model.The efficacy data for the intervention group came from clinical trials,while control group efficacy data were derived from clinical trials,real-world studies,or literature reviews.Efficacy data were either patient-level data or simulated from KM curves.Utilities were mostly obtained from published literature,and costs were all direct costs,mainly from published literature and medical insurance databases.The main outcome measures were quality-adjusted life years(QALYs)and life years(LYs).Sensitivity analysis used deterministic sensitivity analysis and probabilistic sensitivity analysis,with the main influencing factors being drug costs.CONCLUTION There are few existing economic evaluations of R/R MCL both domestically and internationally.Pharmacoeconomic evaluation reports do not strictly adhere to the requirements of the CHEERS scale,with issues of incomplete content.There are still some deficiencies in research time limits in model settings,acquisition of utility data,cost composition,which needs to be urgently addressed in the future.
作者
谭玉洁
徐伟
经天宇
TAN Yujie;XU Wei;JING Tianyu(School of International Pharmaceutical Business,China Pharmaceutical University,Jiangsu Nanjing 211198,China)
出处
《中国医院药学杂志》
北大核心
2025年第6期660-667,共8页
Chinese Journal of Hospital Pharmacy
基金
中国药科大学课题(编号:校合2023-商135)。
关键词
复发或难治性套细胞淋巴瘤
药物经济学评价
系统评价
relapsed or refractory mantle cell lymphoma
pharmacoeconomic evaluation
systematic review
